PVLA Competitors & Alternatives
Compare Palvella Therapeutics, Inc with similar stocks in the same industry
Biotechnology
PVLA
Main Stock$145.03
-4.89%
Tradestie Score
49
Market Cap
$699.30M
Analyst Upside
+61.2%
Supply-Chain & Ecosystem Map (Customers, Suppliers & Direct Competitors)
Bottleneck Score: 2/10
Drug Discovery Biotech
Drug Design
Major Customers
5
specialty pharmacies
dermatology clinics
rare disease patients
academic medical centers
biopharma partners
Critical Suppliers
5
contract manufacturing organizations
API suppliers for rapamycin
clinical research organizations
regulatory consultants
cold-chain logistics providers
Top Competitors
215 stocks in Biotechnology| Company | Price | Market Cap | P/E | Score | Action |
|---|---|---|---|---|---|
|
ARQT
Arcutis Biotherapeutics, Inc. Common Stock
|
$27.19
-3.79%
|
$2.37B | 125.1 | 62 | Compare |
|
APGE
Apogee Therapeutics, Inc. Common Stock
|
$135.07
-0.01%
|
$2.35B | - | 54 | Compare |
|
IBRX
ImmunityBio, Inc. Common Stock
|
$6.03
+0.08%
|
$2.34B | - | 50 | Compare |
|
IRON
Disc Medicine, Inc. Common Stock
|
$77.72
-2.86%
|
$2.33B | - | 47 | Compare |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$30.42
-3.70%
|
$2.33B | - | 59 | Compare |
|
GLPG
Galapagos NV
|
$27.73
-3.75%
|
$2.31B | 5.1 | 47 | Compare |
|
RXRX
Recursion Pharmaceuticals, Inc. Class A Common Stock
|
$2.91
-8.79%
|
$2.23B | - | 50 | Compare |
|
ADPT
Adaptive Biotechnologies Corporation Common Stock
|
$28.00
-3.58%
|
$2.22B | - | 45 | Compare |
|
TVTX
Travere Therapeutics, Inc. Common Stock
|
$49.90
-1.48%
|
$2.21B | - | 59 | Compare |
|
DNLI
Denali Therapeutics Inc. Common Stock
|
$18.33
-2.19%
|
$2.18B | - | 51 | Compare |
More PVLA Analysis
Data updated: Nov 16, 2026 | Industry: Biotechnology (SIC 2834)
215 stocks in this industry